SAN DIEGO--(BUSINESS WIRE)--TrovaGene, Inc. (Pink Sheets:TROV), a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled “Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine.”
